Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

被引：7

作者：

Tomita, Yoshihiko ^{[1
]}

Motzer, Robert J. ^{[2
]}

Choueiri, Toni K. ^{[3
,4
]}

Rini, Brian I. ^{[5
]}

Miyake, Hideaki ^{[6
]}

Uemura, Hirotsugu ^{[7
]}

Albiges, Laurence ^{[8
]}

Fujii, Yosuke ^{[9
]}

Umeyama, Yoshiko ^{[9
]}

Wang Jing ^{[10
]}

Mariani, Mariangela ^{[11
]}

Schmidinger, Manuela ^{[12
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[6] Hamamatsu Univ, Sch Med, Dept Urol, Hamamatsu, Shizuoka, Japan

[7] Kindai Univ, Fac Med, Dept Urol, Osaka, Japan

[8] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[9] Pfizer R&D Japan, Tokyo, Japan

[10] Pfizer Inc, Cambridge, MA USA

[11] Pfizer SRL, Milan, Italy

[12] Med Univ Vienna, Vienna, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.301

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

301

引用

页数：2

共 50 条

[1] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
Haanen, John B. A. G.
Larkin, James
Choueiri, Toni K.
Albiges, Laurence
Rini, Brian I.
Atkins, Michael B.
Schmidinger, Manuela
Penkov, Konstantin
Thomaidou, Despina
Wang, Jing
Mariani, Mariangela
Di Pietro, Alessandra
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
Tomita, Yoshihiko
Motzer, Robert J.
Choueiri, Toni K.
Rini, Brian I.
Miyake, Hideaki
Oya, Mototsugu
Albiges, Laurence
Fujii, Yosuke
Umeyama, Yoshiko
Wang Jing
Di Pietro, Alessandra
Schmidinger, Manuela
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[3] Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
Tomita, Y.
Motzer, R. J.
Choueiri, T. K.
Rini, B., I
Miyake, H.
Uemura, H.
Albiges, L.
Fujii, Y.
Umeyama, Y.
Wang, J.
Mariani, M.
Schmidinger, M.
ESMO OPEN, 2022, 7 (02)
[4] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Albiges, Laurence
Haanen, John B. A. G.
Larkin, James M. G.
Uemura, Motohide
Pal, Sumanta K.
Gravis, Gwenaelle
Campbell, Matthew T.
Penkov, Konstantin
Lee, Jae-Lyun
Ching, Keith A.
Mu, Xinmeng Jasmine
Wang, Xiao
Zhang, Weidong
Wang, Jing
Chudnovsky, Aleksander
di Pietro, Alessandra
Robbins, Paul B.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Motzer, Robert J.
Campbell, Matthew T.
Alekseev, Boris Y.
Uemura, Motohide
Kollmannsberger, Christian K.
Gravis, Gwenaelle
Bjarnason, Georg A.
Gurney, Howard
Chung, Jinsoo
Haanen, John B. A. G.
Rini, Brian I.
Larkin, James M. G.
Schmidinger, Manuela
Nole, Franco
Chudnovsky, Aleksander
Huang, Bo
Hariharan, Subramanian
di Pietro, Alessandra
Albiges, Laurence
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[6] Efficacy of avelumab plus axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101
Haanen, John
Larkin, James
Choueiri, Toni
Albiges, Laurence
Rini, Brian
Atkins, Michael
Schmidinger, Manuela
Penkov, Konstantin
Thomaidou, Despina
Wang, Jing
Mariani, Mariangela
di Pietro, Alessandra
Motzer, Robert
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 51 - 51
[7] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Donahue, Amber C.
Rini, Brian I.
Powles, Thomas
Haanen, John B. A. G.
Larkin, James
Mu, Xinmeng Jasmine
Pu, Jie
Thomaidou, Despina
Di Pietro, Alessandra
Robbins, Paul B.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Association of C-reactive protein (CRP) with efficacy of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
Tomita, Yoshihiko
Larkin, James
Venugopal, Balaji
Haanen, John B. A. G.
Kanayama, Hiro-Omi
Eto, Masatoshi
Grimm, Marc-Oliver
Fujii, Yosuke
Umeyama, Yoshiko
Mariani, Mariangela
Di Pietro, Alessandra
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S)
Jonasch, Eric
Hasanov, Elshad
Motzer, Robert J.
Hariharan, Subramanian
Choueiri, Toni K.
Huang, Bo
Haanen, John B. A. G.
Albiges, Laurence
Venugopal, Balaji
Schmidinger, Manuela
Larkin, James M. G.
Grimm, Marc-Oliver
Negrier, Sylvie
Wang, Jing
Mariani, Mariangela
Chudnovsky, Aleksander
di Pietro, Alessandra
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[10] Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Choueiri, T. K.
Motzer, R. J.
Rini, B., I
Haanen, J.
Campbell, M. T.
Venugopal, B.
Kollmannsberger, C.
Gravis-Mescam, G.
Uemura, M.
Lee, J. L.
Grimm, M-O
Gurney, H.
Schmidinger, M.
Larkin, J.
Atkins, M. B.
Pal, S. K.
Wang, J.
Mariani, M.
Krishnaswami, S.
Cislo, P.
Chudnovsky, A.
Fowst, C.
Huang, B.
di Pietro, A.
Albiges, L.
ANNALS OF ONCOLOGY, 2020, 31 (08) : 1030 - 1039

← 1 2 3 4 5 →